Expectant management for men with early stage prostate cancer

CA Cancer Journal for Clinicians

Volumn 65, Issue 4, 2015, Pages 264-282

  Filson, Christopher P ^a   Marks, Leonard S ^a   Litwin, Mark S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

active surveillance; expectant management; prostate cancer; watchful waiting

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ACTIVE SURVEILLANCE; AFRICAN AMERICAN; ANXIETY; CANCER MORTALITY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COMORBIDITY; CONSERVATIVE TREATMENT; DECISION SUPPORT SYSTEM; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; EXPECTANT MANAGEMENT; GLEASON SCORE; HEALTH CARE DISPARITY; HUMAN; IMAGE GUIDED BIOPSY; INTERMEDIATE RISK PATIENT; LIFE EXPECTANCY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SURVIVAL; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FREE SURVIVAL; URINE INCONTINENCE; WATCHFUL WAITING; ADJUVANT THERAPY; DISEASE COURSE; EARLY DIAGNOSIS; MORTALITY; PALLIATIVE THERAPY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; MALE; PALLIATIVE CARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84936846959     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21278     Document Type: Review

References (184)

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR,. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22: 2141-2149.
2. Galper SL, Chen M-H, Catalona WJ, Roehl KA, Richie JP, D'Amico AV,. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol. 2006; 175: 907-912.
3. Albertsen PC, Hanley JA, Fine J,. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293: 2095-2101.
4. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
5. Loeb S, Bjurlin MA, Nicholson J, et al., Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014; 65: 1046-1055.
6. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P,. Prevalence of latent prostate carcinoma in two US populations. J Nat Cancer Inst. 1980; 65: 311-316.
7. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD,. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol. 1996; 30: 138-144.
8. Moutzouris G, Barbatis C, Plastiras D, et al., Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol. 1999; 33: 27-30.
9. Abbas F, Hochberg D, Civantos F, Soloway M,. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol. 1996; 30: 322-326.
10. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ,. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol. 2011; 29: 464-467.
11. Xia J, Trock BJ, Cooperberg MR, et al., Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012; 18: 5471-5478.
12. Sanda MG, Dunn RL, Michalski J, et al., Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
13. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 185-191.
14. Whitmore WF, Adolfsson J, Steineck G,. Conservative management of localized prostatic cancer. Am J Clin Oncol. 1992; 15: 446-452.
15. Holmberg L, Bill-Axelson A, Helgesen F, et al., A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002; 347: 781-789.
16. Wilt TJ, Brawer MK, Jones KM, et al., Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.
17. Albertsen PC,. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975-980.
18. Bill-Axelson A, Holmberg L, Ruutu M, et al,; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352: 1977-1984.
19. Bill-Axelson A, Holmberg L, Ruutu M, et al,; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011; 364: 1708-1717.
20. Daskivich TJ, Fan KH, Koyama T,. Effect of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer. Ann Intern Med. 2013; 158: 709-717.
21. Draisma G, Etzioni R, Tsodikov A, et al., Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009; 101: 374-383.
22. Eggener SE, Scardino PT, Walsh PC, et al., Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011; 185: 869-875.
23. Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB,. Radical prostatectomy outcome in men 65 Years old or older with low risk prostate cancer. J Urol. 2012; 187: 1620-1625.
24. Busch J, Magheli A, Leva N, et al., Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU Int. 2014; 114: 517-521.
25. Choo R, Klotz L, Danjoux C, et al., Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002; 167: 1664-1669.
26. Carter HB, Kettermann A, Warlick C, et al., Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007; 178: 2359-2365.
27. Klotz L, Vesprini D, Sethukavalan P, et al., Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015; 33: 272-277
28. Tosoian JJ, Trock BJ, Landis P, et al., Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011; 29: 2185-2190.
29. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J,. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol. 2013; 63: 101-107.
30. Bul M, van den Bergh RCN, Zhu X, et al., Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012; 110: 1672-1677.
31. Miocinovic R, Jones JS, Pujara AC, Klein EA, Stephenson AJ,. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology. 2011; 77: 980-984.
32. Adamy A, Yee DS, Matsushita K, et al., Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011; 185: 477-482.
33. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M,. Active surveillance: a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 2008; 101: 165-169.
34. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M,. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010; 58: 831-835.
35. Bul M, Zhu X, Valdagni R, et al., Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013; 63: 597-603.
36. Ischia JJ, Pang CY, Tay YK, Suen CF, Aw HC, Frydenberg M,. Active surveillance for prostate cancer: an Australian experience. BJU Int. 2012; 109: 40-43.
37. Thomsen FB, Roder MA, Hvarness H, Iversen P, Brasso K,. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J. 2013; 60: A4575-A4575.
38. Dall'Era MA, Konety BR, Cowan JE, et al., Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008; 112: 2664-2670.
39. Welty CJ, Cowan JE, Nguyen H, et al., Extended follow-up and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015; 193: 807-811.
40. Selvadurai ED, Singhera M, Thomas K, et al., Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol. 2013; 64: 981-987.
41. Barayan GA, Brimo F, Bégin LR, et al., Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort [serial online]. BJU Int. 2014; 11 (6B): E99-E104.
42. Hernández V, Blázquez C, de la Peña E, Pérez-Fernández E, Díaz FJ, Llorente C,. Active surveillance in low-risk prostate cancer. Patient acceptance and results. Actas Urol Esp. 2013; 37: 533-537.
43. Becker A, Seiler D, Kwiatkowski M, et al., A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. World J Urol. 2014; 32: 891-897.
44. Matthew Andrews J, Ashfield JE, Morse M, Whelan TF,. Five-year follow-up of active surveillance for prostate cancer: a Canadian community-based urological experience. Can Urol Assoc J. 2014; 8 (11-12): E768-E774.
45. Ha JY, Kim BH, Park CH, Kim CI,. Early experience with active surveillance in low-risk prostate cancer treated. Korean J Urol. 2014; 55: 167-171.
46. Lane JA, Donovan JL, Davis M, et al., Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol. 2014; 15: 1109-1118.
47. Gleason DF,. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992; 23: 273-279.
48. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005; 29: 1228-1242.
49. Barry MJ, Albertsen PC, Bagshaw MA, et al., Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management. Cancer. 2001; 91: 2302-2314.
50. Andrén O, Fall K, Franzén L, Andersson S-O, Johansson J-E, Rubin MA,. How well does the Gleason score predict prostate cancer death? A 20-year follow-up of a population based cohort in Sweden. J Urol. 2006; 175: 1337-1340.
51. Reese AC, Cooperberg MR, Carroll PR,. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010; 184: 114-119.
52. Charatan FB,. FDA approves test for prostatic cancer. BMJ. 1994; 309: 628-629.
53. Carvalhal GF, Daudi SN, Kan D, et al., Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology. 2010; 76: 1072-1076.
54. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE,. Ability of preoperative serum prostate specific antigen value to predict pathologic stage and DNA ploidy Influence of clinical stage and tumor grade. Urology. 1993; 41: 207-216.
55. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG,. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology. 2002; 59: 740-745.
56. Stamey TA, Johnstone IM, McNeal JE, et al., Preoperative serum prostate specific antigen levels between 2 and 22 ng/mL correlate poorly with post-radical prostatectomy cancer morphology. J Urol. 2002; 167: 103-111.
57. Stamey T, Caldwell M, McNeal J, et al., The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004; 172: 1297-1301.
58. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368-374.
59. Partin AW, Kattan MW, Subong EN, et al., Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA. 1997; 277: 1445-1451.
60. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17: 1499-1507.
61. Stephenson AJ, Kattan MW, Eastham JA, et al., Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009; 27: 4300-4305.
62. D'Amico AV, Whittington R, Malkowicz SB, et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974.
63. Thompson I, Thrasher JB, Aus G, et al., Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131.
64. Heidenreich A, Bastian PJ, Bellmunt J, et al., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014; 65: 124-137.
65. National Comprehensive Cancer Network (NCCN). Active surveillance monitoring more stringent in updated NCCN guidelines for prostate cancer. Fort Washington, PA: NCCN; 2014. nccn.org/about/news/newsinfo.aspx?NewsID=274. Accessed December 15, 2014.
66. Cooperberg M, Pasta D, Elkin E, et al., The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable predictor of disease recurrence after prostatectomy. J Urol. 2005; 173: 1938-1942.
67. Freedland SJ, Aronson WJ, Kane CJ, et al., Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004; 22: 446-453.
68. Moul JW, Douglas TH, McCarthy WF, McLeod DG,. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996; 155: 1667-1673.
69. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA,. Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol. 1997; 15: 1478-1480.
70. Bratt O, Damber JE, Emanuelsson M, Gronberg H,. Hereditary prostate cancer: clinical characteristics and survival. J Urol. 2002; 167: 2423-2426.
71. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH,. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007; 52: 1560-1563.
72. Reese AC, Landis PK, Han M, Epstein JI, Carter HB,. 550 Critical assessment of criteria used to identify men eligible for active surveillance of low risk prostate cancer [serial online]. J Urol. 2013; 189: e226.
73. Ahmed HU, Hu Y, Carter T, et al., Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol. 2011; 186: 458-464.
74. Mohler JL,. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Comp Canc Netw. 2010; 8: 145-145.
75. Social Security Administration. Actuarial Life Table. Baltimore, MD: Social Security Administration; 2014. ssa.gov/oact/STATS/table4c6.html. Accessed December 15, 2014.
76. Walz J, Gallina A, Hutterer G, et al., Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 69: 88-94.
77. Lee SJ, Lindquist K, Segal MR, Covinsky KE,. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006; 295: 801-808.
78. Mohan R, Beydoun H, Beydoun M, et al., Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study. Qual Life Res. 2011; 20: 713-721.
79. Walz J, Gallina A, Saad F, et al., A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007; 25: 3576-3581.
80. Kim HL, Puymon MR, Qin M, Guru K, Mohler JL,. A method for using life tables to estimate lifetime risk for prostate cancer death. J Natl Compr Cancer Netw. 2010; 8: 148-154.
81. Leung KM, Hopman WM, Kawakami J, Challenging the 10-year rule: the accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. Can Urol Assoc J. 2012; 6: 367-373.
82. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL,. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011; 29: 1335-1341.
83. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD,. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008; 180: 1964-1968.
84. Thomsen FB, Christensen IJ, Brasso K, Røder MA, Iversen P,. Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. BJU Int. 2014; 113: E98-E105.
85. Fall K, Garmo H, Andrén O, et al., Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007; 99: 526-532.
86. Ali K, Gunnar A, Jan-Erik D, Hans L, Pa¨r L, Jonas H,. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer. 2007; 120: 170-174.
87. Ross AE, Loeb S, Landis P, et al., Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010; 28: 2810-2816.
88. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB,. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol. 2008; 54: 1073-1080.
89. Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ,. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int. 2012; 109: 508-513.
90. Dall'Era MA, Cowan JE, Simko J, et al., Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011; 107: 1232-1237.
91. Welty CJ, Cooperberg MR, Carroll PR,. Meaningful end points and outcomes in men on active surveillance for early stage prostate cancer. Curr Opin Urol. 2014; 24: 288-292.
92. Dall'Era MA, Albertsen PC, Bangma C, et al., Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012; 62: 976-983.
93. Shappley WV, Kenfield SA, Kasperzyk JL, et al., Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009; 27: 4980-4985.
94. Satkunasivam R, Kulkarni GS, Zlotta AR, et al., Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol. 2013; 190: 91-96.
95. Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR,. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry [published online ahead of print September 18, 2014 ]. Eur Urol. doi: 10.1016/j.eururo.2014.08.074.
96. Steineck G, Helgesen F, Adolfsson J, et al., Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002; 347: 790-796.
97. Johansson E, Steineck G, Holmberg L, et al., Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011; 12: 891-899.
98. Siston AK, Knight SJ, Slimack NP, et al., Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology. 2003; 61: 172-178.
99. van den Bergh RC, Vasarainen H, van der Poel HG, et al., Short-term outcomes of the prospective multicentre "Prostate Cancer Research International: Active Surveillance" study. BJU Int. 2010; 105: 956-962.
100. Vasarainen H, Lokman U, Ruutu M, Taari K, Rannikko A,. Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. BJU Int. 2012; 109: 1614-1619.
101. Fujita K, Landis P, McNeil BK, Pavlovich CP,. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol. 2009; 182: 2664-2669.
102. Braun K, Ahallal Y, Sjoberg DD, et al., Effect of repeated prostate biopsies on erectile function in men on active surveillance for prostate cancer. J Urol. 2014; 191: 744-749.
103. Sooriakumaran P, Calaway A, Sagalovich D, et al., The impact of multiple biopsies on outcomes of nerve-sparing robotic-assisted radical prostatectomy. Int J Impot Res. 2012; 24: 161-164.
104. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M,. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007; 100: 540-543.
105. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR,. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013; 112: E67-E75.
106. Thong MS, Mols F, Kil PJ, Korfage IJ, van de Poll Franse LV,. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int. 2010; 105: 652-658.
107. Vanagas G, Mickeviciene A, Ulys A,. Does quality of life of prostate cancer patients differ by stage and treatment? Scand J Public Health. 2013; 41: 58-64.
108. Daubenmier JJ, Weidner G, Marlin R, et al., Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology. 2006; 67: 125-130.
109. van den Bergh R, Bot ME, Roobol MJ, et al., Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009; 115: 3868-3878.
110. Patel MI, DeConcini DT, Lopez-Corona E, et al., An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004; 171: 1520-1524.
111. Berger ZD, Yeh JC, Carter HB, Pollack CE,. Characteristics and experiences of patients with localized prostate cancer who left an active surveillance program. Patient. 2014; 7: 427-436.
112. Prasad SM, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA, Hu JC,. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014; 32: 2471-2478.
113. Seiler D, Randazzo M, Leupold U, et al., Protocol-based active surveillance for low-risk prostate cancer: anxiety levels in both men and their partners. Urology. 2012; 80: 564-569.
114. Wilcox CB, Gilbourd D, Louie Johnsun M,. Anxiety and health-related quality of life (HRQL) in patients undergoing active surveillance of prostate cancer in an Australian centre. BJU Int. 2014; 113: 64-68.
115. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR,. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008; 180: 1330-1335.
116. Weiner AB, Patel SG, Etzioni R, Eggener SE,. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015; 193: 95-102.
117. Ritch CR, Graves AJ, Keegan KA, et al., Increasing use of observation among men at low risk for prostate cancer mortality. J Urol. 2015; 193: 801-806.
118. Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC,. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol. 2015; 67: 44-50.
119. Filson CP, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC,. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer. J Urol. 2014; 192: 75-81.
120. Feldman-Stewart D, Brundage MD, Hayter C, et al., What questions do patients with curable prostate cancer want answered? Med Decis Making. 2000; 20: 7-19.
121. Anandadas CN, Clarke NW, Davidson SE, et al., Early prostate cancer-which treatment do men prefer and why? BJU Int. 2010; 107: 1762-1768.
122. Sidana A, Hernandez DJ, Feng Z, et al., Treatment decision-making for localized prostate cancer: what younger men choose and why. Prostate. 2012; 72: 58-64.
123. Gorin MA, Soloway CT, Eldefrawy A, Soloway MS,. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology. 2011; 77: 588-591.
124. Davison BJ, Breckon E,. Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. Patient Educ Couns. 2012; 87: 369-374.
125. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F,. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007; 100: 544-551.
126. Ramsey SD, Zeliadt SB, Fedorenko CR, et al., Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011; 29: 3-9.
127. Kim SP, Gross CP, Nguyen PL, et al., Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: results from a national survey of radiation oncologists and urologists. Med Care. 2014; 52: 579-585.
128. Zietman A, Goitein M, Tepper JE,. Technology evolution: is it survival of the fittest? J Clin Oncol. 2010; 28: 4275-4279.
129. Aizer AA, Paly JJ, Zietman AL, et al., Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012; 30: 3071-3076.
130. Ramsey SD, Zeliadt SB, Arora NK, et al., Access to information sources and treatment considerations among men with local stage prostate cancer. Urology. 2009; 74: 509-515.
131. National Institute of Health and Care Excellence (NICE). Prostate Cancer: Diagnosis and Treatment. CG175. London, UK: NICE; 2014. nice.org.uk/guidance/cg175. Accessed December 15, 2014.
132. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Fort Washington, PA: NCCN; 2014. nccn.org/professionals/physician-gls/PDF/prostate.pdf. Accessed December 15, 2014.
133. Turkbey B, Mani H, Shah V, et al., Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011; 186: 1818-1824.
134. Le JD, Stephenson S, Brugger M, et al., Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol. 2014; 192: 1367-1373.
135. Siddiqui MM, Rais-Bahrami S, Truong H, et al., Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013; 64: 713-719.
136. Somford DM, Hamoen EH, Fütterer JJ, et al., The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 2013; 190: 1728-1734.
137. Schoots IG, Petrides N, Giganti F, et al., Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015; 67: 627-636.
138. Hu JC, Chang E, Natarajan S, et al., Targeted prostate biopsy to select men for active surveillance: do the Epstein criteria still apply? J Urol. 2014; 192: 385-390.
139. Barentsz JO, Richenberg J, Clements R, et al., ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22: 746-757.
140. Kirkham APS, Haslam P, Keanie JY, et al., Prostate MRI: who, when, and how? Report from a UK consensus meeting. Clin Radiol. 2013; 68: 1016-1023.
141. Marks LS, Young S, Natarajan S,. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013; 23: 43-50.
142. Natarajan S, Marks LS, Margolis DJA, et al., Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011; 29: 334-342.
143. Watanabe Y, Terai A, Araki T, et al., Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC map: a prospective large-scale cohort study. J Mag Res Imag. 2012; 35: 1414-1421.
144. Sonn GA, Natarajan S, Margolis DJA, et al., Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013; 189: 86-92.
145. Vourganti S, Rastinehad A, Yerram NK, et al., Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012; 188: 2152-2157.
146. Sonn GA, Chang E, Natarajan S, et al., Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014; 65: 809-815.
147. Marliere F, Puech P, Benkirane A, et al., The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer. World J Urol. 2014; 32: 951-958.
148. Margel D, Yap SA, Lawrentschuk N, et al., Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol. 2012; 187: 1247-1252.
149. Merrick GS, Gutman S, Andreini H, et al., Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol. 2007; 52: 715-724.
150. Taira AV, Merrick GS, Galbreath RW, et al., Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Pros Cancer Prostatic Dis. 2010; 13: 71-77.
151. Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, Young PR,. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology. 2005; 65: 735-739.
152. Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H,. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int. 2012; 110: 993-997.
153. Buskirk SJ, Pinkstaff DM, Petrou SP, et al., Acute urinary retention after transperineal template-guided prostate biopsy. Int J Rad Oncol Biol Physics. 2004; 59: 1360-1366.
154. Pepe P, Aragona F,. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology. 2013; 81: 1142-1146.
155. Marks LS, Fradet Y, Lim Deras I, et al., PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69: 532-535.
156. Rittenhouse H, Blase A, Shamel B, Schalken J, Groskopf J,. The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem. 2013; 59: 32-34.
157. Whitman EJ, Groskopf J, Ali A, et al., PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008; 180: 1975-1979.
158. Auprich M, Chun FKH, Ward JF, et al., Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011; 59: 96-105.
159. Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A,. Urinary PCA3 score predicts prostate cancer multifocality. J Urol. 2011; 185: 1234-1239.
160. Tosoian JJ, Loeb S, Kettermann A, et al., Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol. 2010; 183: 534-538.
161. Loeb S, Catalona WJ,. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014; 6: 74-77.
162. Parekh DJ, Punnen S, Sjoberg DD, et al., A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer [published online ahead of print October 27, 2014 ]. Eur Urol. doi: 10.1016/j.eururo.2014.10.021.
163. Tosoian JJ, Loeb S, Feng Z, et al., Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol. 2012; 188: 1131-1136.
164. Makarov DV, Isharwal S, Sokoll LJ, et al., Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res. 2009; 15: 7316-7321.
165. Khan MA, Carter HB, Epstein JI, et al., Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003; 170: 2274-2278.
166. Knezevic D, Goddard AD, Natraj N, et al., Analytical validation of the Oncotype DX prostate cancer assay-a clinical RT-PCR assay optimized for prostate needle biopsies [serial online]. BMC Genomics. 2013; 14: 690.
167. Cuzick J, Berney DM, Fisher G, et al., Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012; 106: 1095-1099.
168. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al., A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014; 66: 550-560.
169. Andriole GL, Bostwick DG, Brawley OW, et al., Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362: 1192-1202.
170. Thompson IM, Goodman PJ, Tangen CM, et al., The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215-224.
171. Finelli A, Trottier G, Lawrentschuk N, et al., Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol. 2011; 59: 509-514.
172. Fleshner NE, Lucia MS, Egerdie B, et al., Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379: 1103-1111.
173. Cooperberg MR, Cowan JE, Hilton JF, et al., Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011; 29: 228-234.
174. Freedland SJ, Amling CL, Dorey F, et al., Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002; 60: 670-674.
175. Abern MR, Aronson WJ, Terris MK, et al., Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate. 2013; 73: 409-417.
176. Sundi D, Ross AE, Humphreys EB, et al., African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol. 2013; 31: 2991-2997.
177. Ha Y-S, Salmasi A, Karellas M, et al., Increased incidence of pathologically non-organ confined prostate cancer in African-American men eligible for active surveillance. Urology. 2013; 81: 831-836.
178. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM,. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol. 2014; 191: 60-67.
179. Kaplan AL, Crespi CM, Saucedo JD, Connor SE, Litwin MS, Saigal CS,. Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: baseline results from a shared decision-making trial. Cancer. 2014; 120: 2721-2727.
180. Stacey D, Légaré F, Col NF, et al., Decision aids for people facing health treatment or screening decisions [serial online]. Cochrane Database Syst Rev. 2014; 1: CD001431.
181. Fagerlin A, Rovner D, Stableford S, et al., Patient education materials about the treatment of early stage prostate cancer: a critical review. Ann Intern Med. 2004; 140: 721-728.
182. Hacking B, Wallace L, Scott S, et al., Testing the feasibility, acceptability and effectiveness of a "decision navigation" intervention for early stage prostate cancer patients in Scotland-a randomised controlled trial. Psychooncology. 2013; 22: 1017-1024.
183. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA,. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009; 59: 379-390.
184. Gilbert SM, Sanda MG, Dunn RL, et al., Satisfaction with information used to choose prostate cancer treatment. J Urol. 2014; 191: 1265-1271.